Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eptifibatide

FDA-approved product (injectable, injection), marketed as Eptifibatide, Integrilin.

Registered studies
35
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Eptifibatide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Intermediate coronary syndrome
  • Myocardial infarction
  • Recurrent thrombophlebitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
Platelet Aggregation Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

35registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eptifibatide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eptifibatide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

    NCT01087723 · start 2010-03

    Registered record
    Registry ID
    NCT01087723
    Conditions
    Acute Coronary Syndrome
    Interventions
    Bivalirudin; Heparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2014-08
    Enrolment
    2,198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionBivalirudin; Heparin
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients

    NCT00945308 · start 2009-08

    Registered record
    Registry ID
    NCT00945308
    Conditions
    Acute Myocardial Infarction
    Interventions
    Eptifibatide; Eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-08
    Completion
    2010-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocardial Infarction
    InterventionEptifibatide; Eptifibatide
    PhasePhase 2
    Registry statusUnknown

  • Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

    NCT00894803 · start 2009-07

    Registered record
    Registry ID
    NCT00894803
    Conditions
    Ischemic Stroke; Stroke; Brain Infarction
    Interventions
    Eptifibatide; rt-PA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2012-12
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Stroke; Brain Infarction
    InterventionEptifibatide; rt-PA
    PhasePhase 2
    Registry statusCompleted

  • A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

    NCT00834899 · start 2009-01

    Registered record
    Registry ID
    NCT00834899
    Conditions
    Sickle Cell Disease
    Interventions
    Eptifibatide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2009-01
    Completion
    2012-03
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease
    InterventionEptifibatide; Placebo
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial

    NCT00638976 · start 2007-11

    Registered record
    Registry ID
    NCT00638976
    Conditions
    Cardiovascular Disease
    Interventions
    eptifibatide; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-11
    Completion
    2010-05
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    Interventioneptifibatide; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

    NCT00719914 · start 2007-11

    Registered record
    Registry ID
    NCT00719914
    Conditions
    ST-Elevation Myocardial Infarction
    Interventions
    eptifibatide; eptifibatide; normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-11
    Completion
    2009-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionST-Elevation Myocardial Infarction
    Interventioneptifibatide; eptifibatide; normal saline
    PhasePhase 2
    Registry statusTerminated

  • The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)

    NCT01454440 · start 2007-10

    Registered record
    Registry ID
    NCT01454440
    Conditions
    Coronary Artery Disease
    Interventions
    Eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-10
    Completion
    2009-10
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionEptifibatide
    PhasePhase 4
    Registry statusTerminated

  • Eptifibatide and ST Segment Resolution Following Primary PCI

    NCT00812435 · start 2007-08

    Registered record
    Registry ID
    NCT00812435
    Conditions
    Myocardial Infarction
    Interventions
    eptifibitide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2007-08
    Completion
    2011-03
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    Interventioneptifibitide
    PhasePhase 3
    Registry statusTerminated

  • Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

    NCT01103440 · start 2007-04

    Registered record
    Registry ID
    NCT01103440
    Conditions
    Stable Angina
    Interventions
    Intravenous Glycoprotein inhibitor + ASA, Clopidogrel; Antiplatelet Therapy (ASA, Clopidogrel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-04
    Completion
    2009-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStable Angina
    InterventionIntravenous Glycoprotein inhibitor + ASA, Clopidogrel; Antiplatelet Therapy (ASA, Clopidogrel)
    PhasePhase 2
    Registry statusCompleted

  • Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

    NCT00426751 · start 2006-10

    Registered record
    Registry ID
    NCT00426751
    Conditions
    Infarction, Myocardial
    Interventions
    Abciximab; Eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-10
    Completion
    2007-12
    Enrolment
    429

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfarction, Myocardial
    InterventionAbciximab; Eptifibatide
    PhasePhase 3
    Registry statusCompleted

  • Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

    NCT00317395 · start 2006-06

    Registered record
    Registry ID
    NCT00317395
    Conditions
    Coronary Disease
    Interventions
    Otamixaban (XRP0673); unfractionated heparin; eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2009-03
    Enrolment
    3,241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Disease
    InterventionOtamixaban (XRP0673); unfractionated heparin; eptifibatide
    PhasePhase 2
    Registry statusCompleted

  • Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

    NCT00289601 · start 2006-03

    Registered record
    Registry ID
    NCT00289601
    Conditions
    Angioplasty
    Interventions
    eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2006-03
    Completion
    2007-12
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngioplasty
    Interventioneptifibatide
    PhasePhase 4
    Registry statusTerminated

  • Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin

    NCT00370045 · start 2006-03

    Registered record
    Registry ID
    NCT00370045
    Conditions
    Coronary Artery Disease
    Interventions
    Bivalirudin with and without eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2006-03
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionBivalirudin with and without eptifibatide
    PhasePhase 4
    Registry statusUnknown

  • Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)

    NCT00251823 · start 2005-07

    Registered record
    Registry ID
    NCT00251823
    Conditions
    Myocardial Infarction
    Interventions
    Eptifibatide facilitated PCI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-07
    Completion
    2008-09
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    InterventionEptifibatide facilitated PCI
    PhasePhase 3
    Registry statusCompleted

  • Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

    NCT01863134 · start 2005-01

    Registered record
    Registry ID
    NCT01863134
    Conditions
    Non ST Elevation Myocardial Infarction
    Interventions
    Eptifibatide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01
    Completion
    2010-12
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon ST Elevation Myocardial Infarction
    InterventionEptifibatide; Placebo
    PhasePhase 4
    Registry statusCompleted